Webcast scheduled for Wednesday, November 3 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Oct. 20, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3 rd at 11:30 a.m.
Ionis’ partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
– In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed –
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 ( SOD1 )
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
– Sam Tsimikas, M.D., senior vice president of clinical development, to moderate symposium on ATTR-CM – CARDIO-TTRansform, a Phase 3 study of eplontersen for the treatment of ATTR-CM, will be featured on the Patients Association Channel – Multiple presentations highlight new data and research into
Ionis reports second quarter 2021 financial results and recent business achievements
Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics’ technology potentially expands LICA technology capabilities Webcast today, August 4, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Aug.